Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

magazine

Will Vectura update on key drug?

Company has struggled since the launch of Hikma’s asthma treatment was blocked
Thursday 31 Aug 2017 Author: Lisa-Marie Janes
Week Ahead

Wednesday 6 September

It has been a difficult year for pharmaceuticals firm Vectura (VEC). Since May, the company’s share price has plummeted by 25% after the US Food and Drug Administration temporarily blocked the launch of Hikma’s (HIK) generic asthma treatment VR315.

This had a negative read-across for Vectura as VR315 is based on its dry powder inhaler tech so investors will be keen for updates on a potential launch when the firm reports its interim results on 6 September.

‹ Previous2017-08-31Next ›


31 Aug 2017

Download PDF

Page flip version

Important information:

These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.

Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.

Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.

The Shares team
Disclaimer

Issue contents

Big News

Editor's View

Funds

Great Ideas

Great Ideas Update

Larger Companies

Main Feature

Money Matters

Smaller Companies

Story In Numbers

Talking Point

Week Ahead

Magazine archive


31 Jul 2025
24 Jul 2025
17 Jul 2025

10 Jul 2025
3 Jul 2025
26 Jun 2025

19 Jun 2025
12 Jun 2025
5 Jun 2025